Karyopharm Therapeutics | KPTI - Loan Capital


Karyopharm Therapeutics reported $278.22M in Loan Capital for its fiscal quarter ending in December of 2025.





Loan Capital Change Date
AbbVie USD 58.94B 4.03B Dec/2025
Abbott USD 29.64B 19.74B Mar/2026
Amgen USD 51.89B 1.88B Mar/2026
AstraZeneca USD 25.96B 177M Mar/2026
BioCryst Pharmaceuticals USD 395.2M 33.48M Mar/2026
Bristol-Myers Squibb USD 42.15B 698M Mar/2026
Eli Lilly USD 39.37B 1.5B Mar/2026
Enanta Pharmaceuticals USD 0 0 Dec/2024
GlaxoSmithKline GBP 14.01B 696M Mar/2026
Incyte USD 29.41M 785K Mar/2026
J&J USD 37.53B 1.91B Mar/2026
Karyopharm Therapeutics USD 278.22M 278.22M Dec/2025
MacroGenics USD 70M 256K Dec/2025
Merck USD 46.67B 77M Mar/2026
Nektar Therapeutics USD 63.16M 44.35M Dec/2025
Novartis USD 37.45B 7.86B Mar/2026
Novartis USD 29.59B 5.35B Dec/2025
Pfizer USD 60.57B 1.08B Mar/2026
Regeneron Pharmaceuticals USD 1.99B 719.7M Mar/2026
Roche Holding CHF 27.43B 966M Dec/2025
Sangamo BioSciences USD 0 0 Jun/2022
Takeda JPY 4.37T 99.51B Mar/2026
Tectonic Therapeutic USD 43K 57K Dec/2025
TG Therapeutics USD 745.14M 499.5M Mar/2026
Ultragenyx Pharmaceutical USD 1.13B 19M Mar/2026
Xencor USD 82.12M 5.64M Mar/2026